PIRAN, Slovenia/BELGRADE, Serbia, Sept. 1 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) financed the participation of Dr. Ivana Gadjanski in the International Summer School for Stem Cells and Regenerative Medicine held in Piran, Slovenia (21-29. Aug 2009) where a number of eminent speakers presented their work. Among them were Dr. Stephen Minger from King's College, London; Dr. Smadar Cohen from Ben-Gurion University of the Negev, Israel; Dr. Thomas Ekstrom from Karolinska Institute, Stockholm, Sweden; Dr. Zoran Ivanovic from EFS, Bordeaux, France; Dr. Dasa Cziskova from Institute of Neurobiology, Kosice, Slovakia, Dr. Tanja Dominko and Dr. Raymond L. Page from Worcester Polytechnic Institute, USA, Dr. Darja Marolt from Columbia University, USA. Several main topics were discussed: stem cell sources most suitable for clinical application, ethical issues related to stem cell use, obstacles of stem cell therapy (e.g. teratoma formation), future clinical trials (the most interest evokes the FDA-approved world's first human clinical trial of an embryonic stem cell-based therapy for acute spinal cord injury which will be perfomed by Geron using their human embrionic stem cell-derived oligodendrocytes GRNOPC1. The Investigational New Drug Application is currently on clinical hold by the FDA pending the agency's review of new nonclinical animal study data submitted by the company. More information availaible from http://www.geron.com/patients/clinicaltrials/hESC.aspx). Also more technical issues were discussed, e.g. types of biomaterials used for scaffolds, types of bioreactors for growing cells, protocols for cell isolation from various tissues, ways of inducing pluripotency in somatic stem cells (producing iPS), using umbilical cord blood as a source of stem cells. Very promising are adipose-derived stem cells (APC), where first reports are available on the in vivo bone formation and bone augmentation using APC. This type of stem cells raises the least ethical issues and might hold the highest potential for clinical application. However, the takehome message of the whole symposium was that the major task should be to stimulate endogenous potential for repair rather than to force usage of stem cell therapy per se.
The company intends to provide further updates on a timely basis.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact email@example.com; For any corporate matters, please contact firstname.lastname@example.org, www.htdsmedical.com
Related medicine technology :1
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved
. New Assessment Quantifies Risks and Benefits of Warfarin Treatment for Atrial Fibrillation2
. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy3
. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes4
. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies5
. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study6
. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes7
. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks8
. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer9
. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss10
. Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors11
. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia